We present a 74-year-old female patient who developed a pityriasis lichenoides chronica (PLC) during etanercept therapy. This association is not described in the literature and might be considered in the spectrum of cutaneous adverse reactions of etanercept
Disseminated superficial actinic porokeratosis (DSAP) is an uncommon skin condition that can be inhe...
Hemophagocytic syndrome (HPS) is a severe, potentially life-threatening disorder characterized by an...
The tumor necrosis factor alpha (TNF\u3b1) inhibitors have been used with good clinical results in t...
Copyright © 2015 Andrés F. Echeverri et al. This is an open access article distributed under the Cr...
Introduction : Pityriasis licehnoides (PL) exhibits a protean clinical presentation, particularly in...
Herein, we present three cases of Pityriasis lichenoides chronica (PLC) in patients who developed th...
Three patients with atypical courses and manifestations of pityriasis lichenoides chronica (PLC) are...
Background: Lymphomatoid drug reactions can mimic endogenous T and B cell lymphoproliferative diseas...
Tumor necrosis factor-alpha (TNF-α) is a proinflammatory cytokine produced predominantly by activate...
Etanercept is a competitive inhibitor of tumor necrosis factor-alpha (TNF-α) a polypeptide hormone, ...
Hemophagocytic syndrome (HPS) is a severe, potentially life-threatening disorder characterized by an...
Certolizumab is a monoclonal antibody against tumour necrosis factor-alpha (TNF-α) commonly used in ...
Summary We report the case of a patient with rheumatoid arthritis who, after 2 months of treatment w...
Acute generalized exanthematous pustulosis (AGEP) is a skin eruption that is primarily drug induc...
Etanercept is an inhibitor of the pro-inflammatory and immunor-egulatory cytokine tumor necrosis fac...
Disseminated superficial actinic porokeratosis (DSAP) is an uncommon skin condition that can be inhe...
Hemophagocytic syndrome (HPS) is a severe, potentially life-threatening disorder characterized by an...
The tumor necrosis factor alpha (TNF\u3b1) inhibitors have been used with good clinical results in t...
Copyright © 2015 Andrés F. Echeverri et al. This is an open access article distributed under the Cr...
Introduction : Pityriasis licehnoides (PL) exhibits a protean clinical presentation, particularly in...
Herein, we present three cases of Pityriasis lichenoides chronica (PLC) in patients who developed th...
Three patients with atypical courses and manifestations of pityriasis lichenoides chronica (PLC) are...
Background: Lymphomatoid drug reactions can mimic endogenous T and B cell lymphoproliferative diseas...
Tumor necrosis factor-alpha (TNF-α) is a proinflammatory cytokine produced predominantly by activate...
Etanercept is a competitive inhibitor of tumor necrosis factor-alpha (TNF-α) a polypeptide hormone, ...
Hemophagocytic syndrome (HPS) is a severe, potentially life-threatening disorder characterized by an...
Certolizumab is a monoclonal antibody against tumour necrosis factor-alpha (TNF-α) commonly used in ...
Summary We report the case of a patient with rheumatoid arthritis who, after 2 months of treatment w...
Acute generalized exanthematous pustulosis (AGEP) is a skin eruption that is primarily drug induc...
Etanercept is an inhibitor of the pro-inflammatory and immunor-egulatory cytokine tumor necrosis fac...
Disseminated superficial actinic porokeratosis (DSAP) is an uncommon skin condition that can be inhe...
Hemophagocytic syndrome (HPS) is a severe, potentially life-threatening disorder characterized by an...
The tumor necrosis factor alpha (TNF\u3b1) inhibitors have been used with good clinical results in t...